Clinical Trial Detail

NCT ID NCT02252887
Title Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Gemcitabine + Pertuzumab + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST